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Abstract
Amyloid-reactive IgGs isolated from pooled blood of normal individuals (pAbs) have demon-
strated clinical utility for amyloid diseases by in vivo targeting and clearing amyloidogenic
proteins and peptides. We now report the following three novel findings on pAb conformer's
binding to amyloidogenic aggregates: 1) pAb aggregates have greater activity than mono-
mers (HMW species > dimers >monomers), 2) pAbs interactions with amyloidogenic aggre-
gates at least partially involves unconventional (non-CDR) interactions of F(ab) regions,
and 3) pAb's activity can be easily modulated by trace aggregates generated during sample
processing. Specifically, we show that HMW aggregates and dimeric pAbs present in com-
mercial preparations of pAbs, intravenous immunoglobulin (IVIg), had up to ~200- and ~7-
fold stronger binding to aggregates of Aβ and transthyretin (TTR) than the monomeric anti-
body. Notably, HMW aggregates were primarily responsible for the enhanced anti-amyloid
activities of Aβ- and Cibacron blue-isolated IVIg IgGs. Human pAb conformer's binding to
amyloidogenic aggregates was retained in normal human sera, and mimicked by murine
pAbs isolated from normal pooled plasmas. An unconventional (non-CDR) component to
pAb's activity was indicated from control human mAbs, generated against non-amyloid tar-
gets, binding to aggregated Aβ and TTR. Similar to pAbs, HMW and dimeric mAb conform-
ers bound stronger than their monomeric forms to amyloidogenic aggregates. However,
mAbs had lower maximum binding signals, indicating that pAbs were required to saturate a
diverse collection of binding sites. Taken together, our findings strongly support further
investigations on the physiological function and clinical utility of the inherent anti-amyloid
activities of monomeric but not aggregated IgGs.
Introduction
Alzheimer's disease (AD) is the most common of ~30 amyloid disorders that are currently
incurable and often fatal. These diseases involve the extracellular self aggregation of a peptide
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or protein that forms amyloid deposits on organ(s) [1, 2]. Amyloid deposits consist of β-sheet
rich amyloid fibrils and accessory molecules [2, 3]. AD is a particularly complex disease since it
involves the aberrant aggregation of amyloidogenic amyloid β peptides (Aβ) and the microtu-
ble-associated tau protein [2, 4–6]. Other debilitating amyloid disorders, are caused by mutant
and wild-type forms of a blood transport protein transthyretin (TTR) that primarily deposit in
the heart and/or nerves [7–10].
Passive vaccination with humanized anti-amyloid monoclonal antibodies (mAbs) is a pri-
mary immunotherapeutic approach for amyloid diseases [11–13]. A recent novel therapeutic
approach for AD has been to boost a patient's pool of amyloid-reactive IgGs using human
intravenous immunoglobulin (IVIg). IVIg contains a diverse repertoire of pooled polyclonal
human IgGs (pAbs), including anti-amyloid IgGs, from plasmas of 1000’s of normal individu-
als [14–16]. The rational for using IVIg for AD is their ability to reduce levels of soluble cere-
bral Aβ while increasing the peptide's blood pool [17, 18]–a process consistent with beneficial
anti-Aβ immunotherapy [11, 17, 18]. In vitro and transgenic mice studies indicate that Aβ-
reactive IVIg IgGs have therapeutic potential for AD [18–26]. Moreover, we have demon-
strated that Aβ-reactive IVIg IgGs are cross-reactive against conformational epitopes on other
amyloidogenic proteins and peptides. Thus, anti-amyloid pAbs isolated from normal human
blood have demonstrated therapeutic potential not only for AD but for other amyloid diseases
[20, 21, 27].
Recently, IVIg was tested in a 18-month phase 3 clinical trial for mild to moderate AD. The
antibody did not meet its primary endpoints, but subgroup analysis indicated that IVIg had a
slight beneficial effect for AD patients that were ApoE4 carriers and had moderate disease [28].
Presumably, IVIg's ineffectiveness may have been because its anti-amyloid activity was not
potent enough, and patients may have benefited more from an IVIg-like preparation that had
enhanced activity [29]. However, the development of a more viable and potent therapeutic
reagent than IVIg has been hampered by our current poor understanding on its anti-amyloid
activity. For example, it has been assumed, and not yet proven, that natural IgGs are the amy-
loid-reactive species in IVIg. To address this, we have now compared the anti-amyloid activi-
ties of IgG conformers (monomer, dimer, and HMW aggregates) contained in IVIg with
conformers present in preparations of pAbs isolated from normal human and murine plasmas,
and control mAbs generated against non-amyloid targets. Our findings strongly indicate that
an IgG's anti-amyloid activity is enhanced when they aggregate (Dimers and HMW species),
and is an intrinsic property that likely has physiological and clinical significance.
Materials and Methods
Proteins, peptides, and chemicals
Wild-type human Aβ1–40 (Aβ), DAEFRHDSGY-EVHHQK LVFF-AEDVGSN
KGA-IIGLMVGGVV, and Aβ in which serine 26 was substituted with cysteine were synthe-
sized and purified by Dr. James I Elliott at Yale University (New Haven, CT). Peptide masses
and purities (>95%) were confirmed by electrospray ionization/ion trap mass spectrometry
and reverse-phase HPLC. Aβ concentration was determined by absorbance at 275 nm using
the molar extinction coefficient for tyrosine (ε275 = 1400 M
-1 cm-1).
Recombinant wild-type human TTR that was>95% pure by SDS-PAGE was obtained from
Athens Research & Technology Inc. (Athens, GA). TTR's concentration was determined by
absorbance at 280 nm using an E280
0.1%of 1.35 [30]. A pure (>95% by SDS-PAGE) recombi-
nant form of a methionylated N-terminal 165 amino acid fragment of human vascular endo-
thelial growth factor A (VEGF-165) was purchased from BioLegend Inc. (San Diego, CA). A
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hydrophobic maize protein, zein, bovine elastin, human DNA, murine extracellular matrix gel,
and chicken ovalbumin were from Sigma-Aldrich (Saint Louis, MO, USA).
Preparations of IVIg (Gammagard liquid1) were provided by Baxter BioScience (Vienna,
Austria). Sterile-filtered pooled normal human and murine plasmas were obtained from Equi-
tech-Bio Inc. (Kerriville, TX). Human myeloma mAbs were from Binding Site Group Ltd (Bir-
mingham, UK). Human IgG1 mAbs, Avastin (anti-VEGF [31]) and Synagis (anti-human
respiratory syncytial virus [32]), were from Genentech, Inc. (San Francisco, CA) and MedIm-
mune LLC (Gaithersburg, MD), respectively. Murine anti-AβmAb, 6E10 [33], and anti-TTR
mAb, 9G6 [34], were from Signet (Dedham, MA)) and Thermo Fisher Scientific Inc. (Wal-
tham, MA), respectively. An anti-HIV-1 gp120 IgG1 MAb, 46–4 [35], was produced in-house
by high density growth of the hybridoma (American Type Culture Collection, Manassas, VA)
in a 1000 mL CELLine bioreactor flask (CL1000, Integra Biosciences AG, Chur, Switzerland).
MAb 46–4 was purified from hybridoma supernatants using a 1 mL HiTrap protein A HP col-
umn (GE Healthcare, Uppsala, Sweden). MAb 46–4's concentration was determined by absor-
bance at 280 nm using an extinction coefficient (E280
0.1%) of 1.4 [36]. Size exclusion
chromatography (SEC) protein standards were obtained from Bio-Rad (Hercules, CA). All
other chemicals were obtained from Sigma-Aldrich and were of the highest purity available.
Preparation of amyloidogenic conformers
WTAβmonomers and fibrils, disulfide cross-linked S26C Aβ dimers and protofibrils gener-
ated from S26C Aβ dimers (PFs), WT TTR fibrils and soluble TTR aggregates (SAgg) were gen-
erated and characterized as previously described [34, 37]. Briefly, pooled SEC fractions of Aβ
monomers (~0.1 mg/mL in 25 mM ammonium acetate, pH 8.5) was generated from ~1 mg/
mL Aβ in 50 mM Tris containing 6M guanidine HCl, pH 8.2 that was loaded onto a Superdex™
75 10/300 GL column (GE Healthcare Bio-Sciences AB, Uppsala Sweden) equilibrated in 25
mM ammonium acetate, pH 8.5. Purity of Aβmonomer fractions was determined by
SDS-PAGE [37]. WT Aβ fibrils were generated from ~0.2 mg/ml of Aβmonomers in PBS con-
taining 0.02% sodium azide, pH 7.4, by incubating the peptide at 37°C for 14 days. Fibrillogen-
esis was judged complete when Thioflavin T (ThT) fluorescence had reached a maximum
plateau value. The reaction product was harvested by centrifugation at 20,200 x g for 30 min at
room temperature, and fibril morphology confirmed by negative contrast EM [37]. Pooled
SEC fractions of S26C Aβ dimers (~0.1 mg/mL in 25 mM ammonium acetate, pH 8.5) were
generated from ~1 mg/mL of oxidized S26C Aβ in 50 mM Tris-HCl containing 6 M guanidine
HCl, pH 8.0, that was loaded onto a HiLoad 16/60 Superdex 75 column (GE Healthcare Bio-
Sciences AB) equilibrated with 25 mM ammonium acetate, pH 8.5. Purity of S26C Aβ dimer
fractions was determined by SDS-PAGE [37]. PFs were generated from S26C Aβ dimers by a
1:1 dilution of the dimeric peptide in 25 mM ammonium acetate, pH 8.5, into 2X PBS, pH 7.4,
and incubating the peptide at 37°C for ~3 days until a maximum ThT fluorescence plateu
value was obtained [37]. PFs morphology in the reaction product was confirmed by EM and by
the retention of ThT-positive Aβ in sample supernatants after bench-top centrifugation
(16,000 x g for 20 min) [37]. WT TTR fibrils were generated by incubating ~0.5 mg/mL of the
native protein for 4 days at 37°C in 400 mM sodium acetate, pH 4.0. Fibrillogenesis was judged
complete by ThT fluorescence, and the fibrillar product harvested and fibrillar morphology
confirmed by EM [34]. SAggs were generated by pelleting WT TTR fibrils, removing the super-
natant, and re-solubilizing the fibrillar protein by adding 0.1% ammonium hydroxide to the
same volume as the discarded supernatant [34]. After ~5min, the solution was neutralized with
the same volume of 0.5 M Tris-HCl (pH 7.0) and centrifuged to remove any trace insoluble
aggregates. Amyloid-like soluble aggregates in the final preparation was confirmed by ThT
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fluorescence and size-exclusion chromatography using a Superdex™ 75 10/300 GL column (GE
Healthcare Bio-Sciences AB).
Immediately before use, soluble Aβ and TTR conformers were centrifuged, 16,000 x g for
20 min at 4°C, to remove any contaminating insoluble aggregates. Native tetrameric TTR was
SEC-purified from trace aggregates using a Superdex 75™ 10/300 GL column (GE Healthcare,
Uppsala, Sweden) equilibrated with PBS, pH 7.4. Amyloidogenic conformers were stored in
working aliquots at -80°C for up to ~3 months.
Electron microscopy
Negative contrast electron microscopy was performed as described previously [37]. Briefly,
10 μl aliquots of each test sample were applied onto duplicate carbon-coated formvar grids
(Electron Microscope Sciences, Washington, PA), cross-linked with 0.5% (v/v) glutaraldehyde
(Ted Pella Inc., Redding, CA), and stained with 2% (w/v) uranyl acetate solution (Ted Pella
Inc.). The grids were examined using a Tecnai™ G2 Spirit BioTWIN electron microscope (FEI,
Hillsboro, OR).
IgG Purification from normal mammalian plasma
Three different purification methods (protein A, protein G and Melon™ gel chromatography)
were used to identify an optimal procedure for isolating pAbs from pooled normal human and
murine plasmas. Protein G purification of pAbs involved diluting plasma 1:5 into binding
buffer (PBS, pH 7.4), passing the sample over a HiTrap protein G HP column (GE Healthcare),
washing the column with binding buffer, and eluting column-bound IgGs with 100 mM Gly-
cine-HCl, pH 2.7, into eppendorf tubes that contained neutralization buffer (1 M Tris, pH 9.0).
Protein A isolation of human pAbs involved a 1:5 into dilution of plasma into binding buffer
(PBS, pH 7.4), passage over a HiTrap protein A HP column (GE Healthcare), and elution with
0.1 M glycine, pH 3.5, into eppendorf tubes containing neutralization buffer. Except for bind-
ing buffer consisting of 1.5 M glycine containing 3 M NaCl, pH 8.9, protein A-isolation of
murine pAbs was carried out in the same manner as for human pAbs. Melon™ gel isolation of
mammalian pAbs from pooled plasmas was determined using 1 mLMelon™ gel columns
(Thermo Fisher Scientific Inc.) as per manufacturer’s instructions. To minimize IgG aggregation,
all purified antibodies were immediately buffer exchanged to a final concentration of ~1 mg/mL
in PBS, pH 7.4, using 40 kDa Zeba spin columns (Thermo Fisher Scientific Inc.). Antibodies
were used immediately, or stored in working aliquots at -20°C. IgG concentrations were deter-
mined by absorbance at 280 nm using an extinction coefficient (E280
0.1%) of 1.4. IgG purities
were established by SDS-PAGE and SEC using a HiPrep 16/60 Sephacryl S-300 HR column
(GE Healthcare).
Dynamic light scattering (DLS)
DLS was used to estimate the size of IgG conformers present in unfractionated, SEC- and affin-
ity column-fractionated IVIg, pAb and mAb samples. DLS was carried out at room tempera-
ture using a DynaPro plate reader (Wyatt Technologies Corp., Santa Barbara, CA) [38].
Briefly, 100 μl aliquots of ~0.02 to ~1 mg/ml antibody samples and buffer blanks were added to
wells of a polystyrene flat bottom 96 well half-area black microplate (cat# 3881, Corning,
Tewksbury MA). DLS readings were performed using 6 to 20 10s acquisitions with auto-atten-
uation. The hydrodynamic radius (Rh), polydisperse indice, and apparent molecular weights
for IgG conformers in each sample were calculated using DYNAMICS V6 software (version
7.1.7.16, Wyatt, Santa Barbara, California).
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Affinity purification of anti-amyloidogenic IgGs
Anti-amyloid IgG conformers were isolated from preparations of IVIg and mAbs using Aβ and
Cibacron blue affinity chromatography, as described [20, 27]. The Aβ column consisted of
S26C Aβ that was solubilized with 0.1 NH4OH and then aggregated at ~0.2 mg/mL in PBS, pH
7.4, for 5 days at 37°C. DLS analysis was used to estimate IgG conformer sizes in column elu-
ants. Affinity purified IgGs were used instantly for ELISA and/or SEC studies.
Protein aggregation
IgG aggregates were generated by heating ~4 mg/mL of SEC-isolated monomeric IVIg or mAb
Avastin in PBS, pH 7.4, in a water bath at 71°C for up to 30 min [39, 40]. Reactions were
stopped by transferring heated samples to ice when light scattering at A400nm had reached ~0.6
or ~3.9 [39]. Soluble IgG aggregates were separated from insoluble species by centrifuging reac-
tion samples at ~16,000 x g for 25 min at room temperature, and collecting the resultant super-
natants and pellets. IgG pellets were resuspended at ~2 mg/mL in PBS, pH 7.4. The amount of
IgG conformers in each sample was determined by SDS-PAGE, MicroBCA assay (Thermo-
Fisher Scientific Inc), and SEC. Amorphous aggregates of chicken ovalbumin were generated
by iodoacetic acid carboxymethylation of the reduced and denatured protein, as described [41].
SEC Purification of IgG conformers
Antibody monomers, dimers, and high molecular weight (HMW) aggregates were isolated
from preparations of IVIg, pAbs and mAbs using a HiPrep 16/60 Sephacryl S-300 HR or a
Superdex 200 Increase 10/300 GL column (GE Healthcare). The columns were equilibrated in
PBS, pH 7.4, and calibrated using gel filtration protein standards (Bio-Rad). The size of IgG
conformers present in SEC fractions was estimated by DLS. SEC fractionated IgGs were used
immediately for ELISA or for generating heat-induced antibody aggregates.
Antibody fragments
F(ab), F(abˈ)2, and Fc fragments of IVIg were generated using antibody fragmentation prepara-
tion kits, as per manufacturer's instructions (cat#s 44985 and 44988; Pierce Biotechnology,
Rockford, IL). Briefly, papain generated F(ab) and Fc fragments were produced by incubating
~10 mg/ml IVIg in Fab digestion buffer (Pierce Biotechnology), pH 10, with papain-immobi-
lized agarose for 5 h at 37°C. F(ab) fragment reaction product was separated from Fcs and
undigested IgGs using 1 mL NAb™ Protein A Plus Spin columns (Pierce Biotechnology). Pepsin
generated F(abˈ)2 fragments were produced by incubating ~10 mg/ml IVIg in F(abˈ)2 digestion
buffer (Pierce Biotechnology), pH 4.4, with pepsin-immobilized agarose for 24 h at 37°C.
F(abˈ)2 fragments were purified from undigested IgG and digested Fc using 1 mL NAb™ Protein
A Plus Spin columns. IgG fragments were confirmed to be>95% pure by non-reducing
SDS-PAGE and by ELISA, using anti-Fc (Jackson ImmunoResearch Laboratories Inc., West
Grove, PA) and anti-γ chain (Sigma-Aldrich) secondary antibodies. IgG fragments were used
immediately or stored in working aliquots at 4°C for up to 1 month.
Antibody binding to amyloidogenic conformers-ELISAs
Direct and competition ELISAs were the primary methods used to establish IgG binding to Aβ
and TTR conformers [21, 27, 41]. ELISA experiments were carried out in duplicate with 1%
BSA in PBS, pH 7.4, as blocking buffer, and assay buffer consisting of blocking buffer contain-
ing 0.05% tween 20. The detection system consisted of a biotinylated goat anti-human or anti-
mouse IgG (γ-specific, Sigma-Aldrich), streptavidin-horse radish peroxidase (Jackson
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ImmunoResearch Laboratories, Inc.), and colorimetric TMB substrate (SureBlue ReserveTM;
KPL, Gaithersburg, MD, USA). Alternatively, plate-bound IgG was detected using the biotiny-
lated secondary antibodies with strepetavidin-Eu+3 and enhancement solution (DELFIA
1
; Per-
kinElmer, Inc., Boston, MA, USA) [21, 41]. Absorbance (A450nm) and Eu
+3 time-resolved
fluorescence (Ex340nm/Em615nm) assay signals were measured using a SpectraMax M2 multi-
detection (Molecular Devices Corp., Sunnyvale, CA) and a Wallac Victor 2 (PerkinElmer, Inc.)
microtiter plate reader, respectively. Antibody binding and competition curves were generated
by subtracting background controls from assay signals. The resultant graphs were fit using a
standard 3-parameter sigmoid (logistic) function (SigmaPlot 2000, version 6; Systat Software,
Chicago, IL). The concentration of antibody that gave half-maximal binding, EC50, and the
concentration of competitor that gave half maximal inhibition, IC50, were determined from the
fitted curves.
The ability of human and murine pAbs to compete with each other for the same or similar
binding sites on amyloidogenic conformers was determined using a hybrid capture/competi-
tion ELISA. The assay established the inhibition of plate-immobilized IVIg F(ab) fragments
(200 ng/well) binding to 8 μg/mL of solution-phase PFs by serially diluted (6 nM to 6 μM)
human and murine pAb competitors. The detection system consisted of an in house pan-Aβ
reactive polyclonal rabbit antibody, AW7 [42], a horse radish peroxidase-conjugated goat anti-
rabbit IgG (GE healthcare), and TMB substrate (SureBlue ReserveTM; KPL). IC50 values were
determined from the sigmoid-fitted curves.
Immunoprecipitation/Western blots
IVIg, pAbs, and mAb binding to Aβ conformers was investigated using duplicate 0.5 ml reac-
tion samples, as previously described [43]. Each sample consisted of 0.5 or 5 μg/mL of an Aβ
conformer and 20, 100, or 200 μg/mL antibody. Positive control immunoprecipitation (IP)
experiments were carried out using an in-house polyclonal pan-Aβ reactive antibody, AW8
[27, 42]. Except for the absence of protein G beads or test antibody, negative control IPs were
setup in the same manner as for test IPs. All samples were incubated for 1 h at room tempera-
ture, beads centrifuged at 4,000 x g for 5 min, pellets washed with IP STEN buffers, and anti-
body-bound Aβ liberated by heating the pellets at 100°C for 5 min in 2 x SDS sample buffer
[43]. The boiled samples were electrophoresed on 16% polyacrylamide tris-tricine gels, trans-
ferred onto 0.2 μm nitrocellulose (Optitran, Schleicher and Schull, Germany) at 400 mA for
2 h. Membrane-bound Aβ was detected by enhanced chemiluminescence (Thermo Fisher Sci-
entific Inc.) using 1 μg/mL of an N-terminal Aβ-reactive mAb 6E10 (7 nM) [43]. In addition,
mAb Avastin's ability to IP Aβ in the presence of a 5 molar excess (with respect to Avastin) of a
N-terminal 165 amino acid fragment of its immunogen VEGF (VEGF-165; BioLegend Inc.)
was determined by Western blots against Aβ, as above, and VEGF-165-bound Avastin, using
1 μg/mL Avastin (7 nM) as the primary antibody.
Results
Human and murine pAbs similarly cross-react with amyloidogenic
aggregates
Fig 1 and Table 1 show that protein A-purified pAbs from pooled normal human plasmas and
IVIg had essentially the same reactivity with plate-immobilized PFs, with EC50s of ~300 nM.
Given pAb preparations each consisted of a heterogenous mix of IgGs, each EC50 value that
was determined was the “apparent” activity for all IgG types in the preparation. The purified
IgGs had the same activity as pAbs present in, or dosed back into pooled normal plasmas
IgG Conformer's Binding to Amyloidogenic Aggregates
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Fig 1. IVIg and Protein A-purified human andmurine pAbs have similar anti-amyloid activities. (A) IgG binding curves against plate-immobilized PFs
for IVIg and protein A-purified human (Hu) and murine (Mu) pAbs from pooled normal plasmas. Antibody binding curves are also shown for pAbs present in or
dosed back into plasma. (B) Hybrid capture/competition ELISA curves for pAb's and IVIg's dose-dependent inhibition of PFs binding by plate-immobilized
IVIg F(ab') fragments. The assay was carried out using 8 μg/ml solution-phase PFs. (C) Antibody binding curves for Hu and Mu pAb's nM cross-reactivity with
plate-immobilized Aβ and TTR fibrils. (D) Left panel: Competition curves for solution-phase PF's and Aβmonomer's (Mon) inhibition of pAbs and IVIg binding
to plate-immobilized PFs. Right panel: SAgg's and native TTR's (Nat) inhibition of pAbs and IVIg binding to plate-immobilized TTR fibrils. Competition studies
were carried out using IgG concentrations, ~500 nM, which were equivalent to their EC50 values for binding to PFs or TTR fibrils. Each binding or competition
curve was carried out in duplicate, and bars represent the standard errors.
doi:10.1371/journal.pone.0137344.g001
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(Fig 1A). The later findings confirmed that protein A was an optimal method for purifying
pAbs since it did not modulate their avidities for PFs. SDS-PAGE and SEC confirmed that our
pAb preparations were highly pure (~95%), and essentially free of plasma IgMs. Nevertheless,
given IgMs can bind to protein A [44], we ensured that any contaminating IgMs did not influ-
ence our ELISA measurements of pAb’s binding to PFs and other amyloidogenic conformers
by using secondary antibodies that were specific for human and murine IgGs (γ heavy chain
specific). In contrast to protein A-isolated pAbs, protein-G purified pAbs had ~5-fold
enhanced PFs reactivity, and Melon gel-isolated pAbs were not sufficiently pure (<70% pure)
to carry out PFs binding studies. Presumably, the protein G-isolated pAb's enhanced activity
was due to the low pH elution buffer's (0.1 M glycine HCl, pH 2.7) artifactual enhancement of
the IgG's polyreactivity [45].
Given IVIg's anti-amyloid activity has been attributed to naturally occurring autoantibodies
[23], we investigated if human pAb's anti-amyloidogenicity could be mimicked by protein A-
isolated pAbs from normal murine plasmas. Fig 1A and Table 1 show that murine and human
pAbs, and IVIg, had essentially the same binding to plate-immobilized PFs. Given the IgG's
similar avidities, we used a hybrid capture/competition ELISA to establish if they competed for
the same or similar binding sites. Fig 1B shows that all three IgGs similarly dose-dependently
inhibited plate-immobilized IVIg F(ab)s binding to PFs, with IC50s of ~3 μM. The IgG's also
cross-reacted with Aβ fibrils, TTR fibrils, and soluble TTR aggregates (SAgg), with EC50s in the
300–600 nM range (Fig 1C, Table 1). Given that surface-adsorbed amyloidogenic conformers
can alter antibody reactivity [20, 46], we investigated if the IgG's could still bind to soluble amy-
loidogenic conformers (PFs and SAgg) in a solution-phase competition ELISA. Fig 1D shows
that PFs, but not Aβmonomers, dose-dependently inhibited the pAbs and IVIg from binding
to plate-immobilized PFs, with IC50s of ~10 μg/mL. In contrast, both Aβmonomers and PFs
potently inhibited a pan-Aβ reactive murine mAb, 6E10 (Signet Laboratories), binding to
plate-immobilized PFs (Fig 1D). Competition ELISA also demonstrated that the pAb's and
IVIg's binding to plate-immobilized TTR fibrils were dose-dependently inhibited by solution-
Table 1. Mammalian IgGs binding to plate-immobilized amyloidogenic conformers. Each value for EC50 and maximum assay signal amplitude was
determined from the average of two to four sigmoidal fitted antibody binding curves, as shown in Figs 1, 2 and 7.
PFs SAgg
IgG Preparation EC50 (nM) Max. Signal (A450nm) EC50 (nM) Max. Signal (A450nm)
Human pAbs Unfractionated 363 ± 3.3 2.5 ± 0.1 619 ± 24 1.2 ± 0.1
SEC mon1 1206 ± 45 2.8 ± 0.3 n.d.3 n.d.
Mouse pAbs Unfractionated 331 ± 4.6 2.1 ± 0.2 261 ± 3.4 1.3 ± 0.2
SEC mon 698 ± 18.6 3.2 ± 0.4 n.d. n.d.
IVIg Unfractionated 269 ± 2.7 2.4 ± 0.2 250 ± 2.0 1.4 ± 0.1
SEC mon 576 ± 26 2.6 ± 0.1 481 ± 4.0 n.d.
SEC dimer2 81 ± 1.0 3.2 ± 0.4 131 ± 1.2 n.d.
Synagis Unfractionated 891 ± 13 0.8 ± 0.3 2523 ± 25 0.8 ± 0.1
mAb SEC mon 1611 ± 30 0.3 ± 0.0 n.d. n.d.
SEC dimer 229 ± 4.6 ~2.0 n.d. n.d.
Avastin Unfractionated 1870 ± 30 0.3 ± 0.0 4130 ± 87 0.7 ± 0.1
mAb SEC mon 3273 ± 78 0.3 ± 0.0 n.d. n.d.
SEC dimer 185 ± 2.1 >0.7 n.d. n.d.
1,2SEC-isolated IgG monomers (mon) and dimers as shown in Fig 2A.
3n.d. stands for not determined.
doi:10.1371/journal.pone.0137344.t001
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phase SAgg, but not by native TTR (Fig 1D). A ~4-fold lower inhibition was obtained for
murine compared with human pAbs, with an IC50 of ~50 μg/mL. In contrast, a pan-TTR reac-
tive mAb 9G6's (Thermo Fisher Scientific Inc.) binding to plate-immobilized TTR fibrils was
inhibited by both native TTR and SAgg (Fig 1D).
PAb binding to amyloidogenic aggregates is enhanced when pAbs
aggregate, and involves F(ab)s of intact IgGs
Having established that human and murine pAbs had similar avidities for amyloidogenic
aggregates, we investigated if their activities depended on IgG conformer type (monomer,
dimer, or high molecular weight (HMW) species). To do this, we SEC-isolated IgG conformers
from preparations of pAbs and IVIg and established their binding to PFs. Fig 2A and Table 1
show that SEC-isolated pAbs and IVIg monomers were ~2- to 3-fold weaker than the unfrac-
tionated antibodies at binding to plate-immobilized PFs, respectively, with EC50s of ~600 nM
to 1 μM (Table 1). SEC fractionation of pAbs and IVIg indicated that their relatively strong
reactivity's with PFs was due to IgG dimers and/or trace amounts of HMW aggregates (Fig
2A). Moreover, SEC-isolated IVIg dimers bound 5- to 10-fold stronger than monomers to PFs
and SAgg, with EC50s of ~80 and 130 nM, respectively (Table 1, Fig 2B). Dynamic light scatter-
ing (DLS) confirmed that IgG monomer and dimer samples were homogenous and>99%
pure, with hydrodynamic radii (Rh) of 4.68 nm (12.8% polydispersity) and 6.53 nm (12.2%
polydispersity), respectively (Fig 2C and 2D).
The enhanced binding of amyloidogenic aggregates by IgG aggregates was further evident
from an enrichment of HMW IgG species in preparations of Aβ column-isolated IVIg IgGs.
SEC chromatographs in Fig 3A show that Aβ-isolated IVIg IgGs, but not the unfractionated
antibody, contained IgG aggregates that primarily eluted near the void volume of the Superdex
200 Increase 10/300 GL column (GE Healthcare). DLS on SEC fractions eluted near the col-
umn void volume (~10–12 mL) confirmed the presence of HMW IgG assemblies with a Rh of
59.1 nm (14.4% polydispersity). DLS analysis of pooled SEC fractions (~12–13 mL) collected
nearer the IgG dimer peak, revealed the presence of two major species: 1) IgG dimers with an
Rh of 6.7 nm that accounted for ~80% of the signal, and 2) HMW species with a Rh of 39 nm
that accounted for 20% of the signal. Control experiments confirmed that IgG aggregates con-
tained in Aβ-isolated IVIg IgG preparations were not induced by the low pH buffer (0.1 M gly-
cine, pH 2.7) that was used to elute the antibodies off the Aβ column (Fig 3A).
ELISA studies with unfractionated and SEC fractionated IgG conformers of Aβ column-iso-
lated IVIg IgGs confirmed that IgG aggregates were primarily responsible for the preparation's
enhanced anti-amyloid activity. Fig 3A and Table 1 show that the ~40-fold enhanced PFs bind-
ing by Aβ-isolated IVIg IgGs compared with the unfractionated antibody was primarily due to
a mixture of aggregate species (dimers and HMW species). The SEC-isolated IgG aggregates
had ~180-fold stronger binding to PFs than unfractionated IVIg, with an EC50 of 1.6 ± 0.1 nM
(Fig 3A, Table 2). Moreover, Aβ-isolated IVIg IgG monomers were ~11-fold stronger than
monomers of unfractionated IVIg at binding to PFs, with an EC50 of 74 ± 1.0 nM (Fig 3A,
Tables 1 and 2). DLS confirmed that Aβ-isolated IgG monomers were highly pure (99.5%), but
contained 0.5% of HMW aggregates with a Rh of 12.1 nm (8.9% polydispersity).
Cibacron blue-isolated IVIg IgGs bound PFs ~15-fold better than the unfractionated anti-
body (Fig 3B and Table 2). SEC fractionation of the same samples revealed that dye-isolated,
and not unfractionated, IVIg contained HMW aggregates (Fig 3B). SEC fractions of dye-iso-
lated HMW IgG aggregates were ~90-fold stronger at binding to PFs than unfractionated IVIg,
with an EC50 of 3.3 ± 0.1 nM (Fig 3B and Table 2). Control experiments confirmed that dye-
isolated IgG aggregates were not induced by the high salt elution buffer (PBS containing 1.5 M
IgG Conformer's Binding to Amyloidogenic Aggregates
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Fig 2. Dimeric pAbs bindmore tightly to PFs than their monomeric form. (A) Left panel: SEC chromatograms for ~1 mg/mL of protein A-purified pAbs
and IVIg in PBS, pH 7.4. SEC was carried out using a Hiprep16/60 Sephacryl S300 HR column (GE Healthcare) that was equilibrated in PBS, pH 7.4. Arrows
indicate the elution of protein molecular weight standards. Right panel: Antibody binding curves against PFs for unfractionated (Unfrac) and SEC-isolated
monomeric pAbs. (B) Left panel: Antibody binding curves against PFs for unfractionated and SEC-isolated monomeric and dimeric IVIg IgGs. Right panel:
SEC chromatographs for ~0.2 mg/ml IVIg dimers and monomers in PBS, pH 7.4, after incubation under ELISA-like conditions (4 h at 37°C). (C) Dynamic light
scattering for 0.8 mg/mL and 0.06 mg/mL of SEC-isolated IVIg monomers and (D) dimers, respectively. Dynamic light scattering was determined at room
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NaCl, pH 7.4) that was used to elute the antibodies off the dye column (Fig 3B). Notably, prep-
arations of dye-isolated IgGs were less enriched in aggregates than Aβ-isolated antibodies, and
consequently had ~3-fold lower binding to PFs, with an EC50 of 22 ± 0.5 nM (Fig 3B and
Table 2). Like Aβ-isolated IVIg monomers, the dye-isolated IVIg monomers were ~8-fold
temperature immediately after SEC-isolation of each IgG conformer in PBS, pH 7.4. Rh and pd are abbreviations for hydrodynamic radius and polydispersity,
respectively.
doi:10.1371/journal.pone.0137344.g002
Fig 3. IgG aggregates are primarily responsible for the enhanced anti-amyloid activities of Aβ- and Cibacron blue-isolated pAb IgGs. (A) Left panel:
SEC chromatograms for ~0.5 mg/mL of Aβ-isolated IVIg IgGs, and for IVIg, untreated, or diluted into column elution buffer (0.1 M glycine, pH 2.7) that was
used to elute Aβ-bound IVIg IgGs. SEC was carried out using a Superdex 200 increase 10/300 GL column (GE Healthcare) that was equilibrated with PBS,
pH 7.4. Right panel: IgG binding curves against plate-immobilized PFs for untreated IVIg, and for Aβ column-isolated IVIg IgGs that were used unfractionated
(Unfrac) or as SEC-isolated monomers (SECMon) or aggregates (SEC Aggs). SEC Aggs consisted of a pool of IgG conformers (dimers and HMW species)
that eluted before the monomeric antibody. (B) Left panel: SEC chromatograms for ~0.5 mg/mL dye-isolated IVIg IgGs, and for unfractionated IVIg that was
untreated or diluted into column elution buffer (PBS containing 1.5 M NaCl, pH 7.4) that was used to elute dye-bound IVIg IgGs. Right panel: IgG binding
curves against plate-immobilized PFs for unfractionated and SEC-isolated conformers of dye-isolated IVIg IgGs, and for untreated IVIg.
doi:10.1371/journal.pone.0137344.g003
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stronger at binding PFs than monomers isolated from unfractionated IVIg, with an EC50 of
104 ± 1.3 nM (Fig 3B).
To further investigate how aggregation of IgGs may give rise to enhanced recognition of
PFs, we used heat-treatment to deliberately induce the formation of IgG aggregates. Fig 4A
shows that heat-induced IVIg aggregates did not have enhanced avidity for plate-immobilized
PFs compared with the native antibody. Nevertheless, maximum PFs binding signals were up
to 50% greater for the aggregated than native antibody (Fig 4A). Moreover, we discovered that
aggregates formed by buffer exchanging ~2 mg/mL IVIg in high salt buffer (Gentle Elution
buffer; Pierce) into PBS had ~20-fold greater avidity for PFs than the untreated antibody, with
an EC50 value of ~40 nM (Fig 4B). As expected, SEC removal of trace HMW aggregates in
preparations of buffer exchanged IVIg abrogated the antibody's enhanced activity (Fig 4B).
Having established IVIg's anti-amyloid activity was due to monomeric and aggregate IgG
conformers, we determined if the conformers retained activity in the presence of normal
human sera or non-amyloid molecules. Fig 5A shows that SEC-isolated IVIg monomers and
dimers, and HMW IgG containing Aβ-isolated IVIg IgGs retained binding to plate-immobi-
lized PFs in the presence of IgG-depleted normal human sera. Consistent with the IgG confor-
mer's retention of activity in human sera, the antibodies maintained binding to PFs in the
presence of Aβmonomers and non-amyloid molecules (Fig 5B). Non-amyloid molecules that
were chosen to investigate the specificities of IgG conformers for PFs was based on their: 1)
Abundance in vivo (extracellular matrix and elastin fibrils), 2) Association with polyreactive
autoantibodies (DNA), 3) High hydrophobicity (maize protein zein), and 4) Non-amyloid
aggregate state (amorphous aggregated carboxymethylated ovalbumin). Although IVIg IgG
conformers retained binding to PFs in the presence of non-amyloid molecules, SEC-isolated
dimers and Aβ-affinity column treated IgG bound stronger to plate-immobilized ECM and
DNA than IgG monomers (Fig 5C).
To determine which region(s) of IgG molecules bound amyloidogenic conformers, we gener-
ated F(abˈ)2, F(ab), and Fc fragments of unfractionated and Cibacron blue-isolated IVIg IgGs.
Fig 6 shows that F(ab) fragments of unfractionated and dye-isolated IgGs bound similarly to
PFs, with EC50s of ~10 and ~3 μM, respectively. Likewise, F(abˈ)2 fragments of the two antibodies
had ~4-fold stronger PFs binding than their F(ab)s, with EC50s of ~3 μM and 627 ± 7 nM,
respectively (Fig 6). SEC confirmed that ~30-fold stronger PFs binding by dye-isolated IVIg
Table 2. Unfractionated, Aβ- and Cibacron blue-isolated human IgGs binding to plate-immobilized PFs. Each value for EC50 and maximum signal
amplitude was determined from the average of two to three sigmoidal fitted antibody binding curves, as shown in Figs 3 and 8.
PFs
IgG Preparation Conformers EC50 (nM) Max. Signal (A450nm)
IVIg Unfractionated Mon1, Dimer, HMW 286 ± 4.3 1.1 ± 0.1
IVIg Aβ-isolated Mon, Dimer, HMW 8.0 ± 0.1 1.4 ± 0.1
SEC mon2 74 ± 1.0 1.7 ± 0.2
SEC dimers/HMW3 1.6 ± 0.1 1.8 ± 0.2
IVIg Dye-isolated Mon, Dimer, HMW 22 ± 0.5 1.2 ± 0.1
SEC mon 104 ± 1.3 1.3 ± 0.0
SEC HMW 3.3 ± 0.1 1.9 ± 0.3
Avastin Unfractionated Mon, Dimer, HMW 1349 ± 113 0.3 ± 0.1
mAb Aβ-isolated SEC HMW 11 ± 0.2 0.4 ± 0.1
1Mon stands for IgG monomers.
2,3SEC-isolated IgG monomers (mon), dimers, and HMW aggregates as shown in Figs 2 & 3.
doi:10.1371/journal.pone.0137344.t002
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IgGs compared with its F(abˈ)2s was due to the presence of aggregates (data not shown). Fc frag-
ments generated from either unfractionated or dye-isolated IVIg IgGs were ineffective at binding
to PFs, with EC50s>10 μM (Fig 6).
Anti-amyloid activity is an inherent property of IgGs
Given the inherent stickiness of amyloidogenic aggregates [47, 48], we investigated if any
human IgG had anti-amyloid activity. Two humanized murine IgG1 mAbs generated against
non-amyloid targets, Avastin (anti-VEGF, Genentech, Inc.) and Synagis (anti-RSV, MedIm-
mune LLC), recognized Aβ aggregates (Fig 7A, Table 1). The mAbs bound up to 7-fold weaker
to plate-immobilized PFs than IVIg, and with up to 8-fold lower maximum signal amplitudes,
with EC50s of ~1 and ~2 μM, respectively. Like IVIg, the two mAbs recognized aggregated, and
Fig 4. PAb aggregates have diverse avidities for Aβ. (A) Left panel: SEC chromatograms for untreated IVIg and for supernatants of ~4 mg/mL of SEC-
isolated monomeric IVIg in PBS, pH 7.4, which was heated at 71°C until light scattering at A400nm was 0.6 or 3.9, respectively. Right panel: Antibody binding
curves against plate-immobilized PFs for untreated IVIg, Aβ-isolated IVIg IgGs, and for IgG supernatants (sup) and PBS resuspendend pellets (pellet) of
heat-treated IVIg. (B) Left panel: SEC chromatograms for ~4 mg/mL of untreated IVIg and for IVIg that was buffer exchanged at room temperature from
gentle elution buffer (Pierce), pH 6.6, into PBS, pH 7.4. Right panel: Antibody binding curves against plate-immobilized PFs for untreated IVIg, buffered
exchanged IVIg that was used unfractionated or as SEC-isolated monomers, and for Aβ-isolated IVIg IgGs.
doi:10.1371/journal.pone.0137344.g004
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not monomeric Aβ (Fig 7B; data not shown), and cross-reacted with soluble TTR aggregates,
SAgg, with EC50s of ~1 μM (data not shown). Moreover, binding of mAb Avastin to a 5-molar
excess of a N-terminal 165 amino acid fragment form of its immunogen (VEGF-165, BioLe-
gend Inc.) did not affect the antibody's ability to immunoprecipitate Aβ dimers and PFs (Fig
7B). Like IVIg, SEC-isolated dimers of Avastin and Synagis were ~15- and ~7-fold stronger
Fig 5. IVIg IgG conformers retain binding to Aβ in the presence of normal human sera and non-amyloid molecules. (A) Antibody binding curves
against plate-immobilized PFs for SEC-isolated IVIg monomers (SECMon), dimers (SEC Dimer), and for Aβ-isolated IVIg IgGs with or without a 1:10 dilution
of IgG-depleted normal human sera. Preparations of Aβ-isolated IVIg IgGs contained HMW, dimeric, and monomeric species (see Fig 3A). (B) Bar charts for
solution-phase PFs, monomeric Aβ and for non-amyloid molecules inhibition of IVIg IgG conformers binding to plate-immobilized PFs. Non-amyloid
molecules were chosen based on their: 1) Abundance in vivo (extracellular matrix and elastin fibrils), 2) Association with polyreactive autoantibodies (DNA),
3) High hydrophobicity (maize protein zein), and 4) Non-amyloid aggregate state [amorphous aggregated carboxymethylated ovalbumin (CM-Oval)].
Competition studies were carried out using 0.1 mg/mL competitors and concentrations of IgG conformers that were equivalent to their EC50 values for PFs:
400 nM IgG Monomers; 50 nM IgG dimers, and 20 nM Aβ-isolated IgGs. Each competition curve was carried out in duplicate, and bars represent the
standard error. (C) IVIg IgG conformer binding curves against PFs and non-amyloid molecules, murine extracellular matrix gel (ECM) and human DNA.
doi:10.1371/journal.pone.0137344.g005
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than monomers at binding to PFs, and had larger maximum signal amplitudes, with EC50s of
~200 nM, respectively (Fig 7 and Table 1). SEC-isolated mAb monomers were ~2-fold weaker
at binding to PFs than the unfractionated antibodies, with EC50s of ~2 μM (Table 1).
Given the mAb's and IVIg's similar abilities to recognize amyloidogenic substrates, we
investigated if Avastin, like IVIg, retained activity in the presence of normal human sera and
non-amyloid molecules. Fig 7 shows that SEC-isolated monomers and dimers of Avastin main-
tained binding to plate-immobilized PFs in the presence of normal human sera or non-amyloid
molecules (Fig 7C and 7D). Dose-dependent competition studies with PFs and several non-
amyloid competitors confirmed that only PFs were a potent inhibitor of Avastin dimers bind-
ing to plate-immobilized PFs, with an IC50 of ~3 μg/mL (S2 Fig). Given the mAb's and IVIg's
similar specificities for amyloidogenic aggregates, we established if, like a polyclonal antibody,
a subpopulation of highly active IgG conformer(s) could be isolated from mAb preparations by
Fig 6. IgG F(ab)ˈs but not Fcmediate IgG binding to PFs. Antibody binding curves are shown against
plate-immobilized PFs for intact and fragmented IgGs from preparations of unfractionated IVIg (A) and for
Cibacron blue-isolated IVIg IgGs (B). Antibody binding studies were carried out in triplicate and bars
represent the standard error.
doi:10.1371/journal.pone.0137344.g006
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Fig 7. A humanmAb generated against a non-amyloid target binds aggregated Aβ. (A) Left panel: SEC chromatograms for ~15 mg/mL of mAb Avastin
(anti-VEGF) and IVIg. SEC was carried out using a Superdex 200 Increase 10/300 GL column (GE Healthcare) equilibrated in PBS, pH 7.4. Right panel:
Antibody binding curves against plate-immobilized PFs for unfractionated (Unfrac) IVIg, and for Avastin used unfractionated or as SEC-isolated monomers
and dimers. (B) The top Western blots show immunoprecipitation (IP) of synthetic Aβ conformers (monomers (Mon), dimers, and PFs) by 100 μg/mL of
Avastin and IVIg, and by 200 μg/mL of a pan-Aβ reactive polyclonal antibody, AW8. The blots were probed for Aβ using an Aβ N-terminal reactive mAb, 6E10
(Signet Laboratories). The lower Western blots show 20 μg/mL mAb Avastin's ability to IP 5 μg/mL of Aβ dimers and PFs in the presence of a 5-molar excess
IgG Conformer's Binding to Amyloidogenic Aggregates
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Aβ affinity chromatography. We successfully isolated Avastin IgGs off the Aβ column, but the
yield (~0.06% of IgGs passed through the column) was ~2-fold lower than for IVIg [27]. Nota-
bly, the yield for Aβ-isolated Avastin IgGs was reduced in half (~0.03%) when Avastin column
flow throughs were passed through the Aβ column a second time. The latter confirmed that
Aβ-isolated Avastin IgGs constituted a discrete antibody subpopulation. The SEC chromato-
graphs in Fig 8A show that Aβ column-isolated Avastin IgGs, like Aβ-isolated IVIg IgGs, con-
tained a substantial amount of aggregates. DLS indicated that the Aβ-isolated Avastin IgG
conformers existed as heterogeneous HMW species [Rh = 9.55 nm (26% polydispersity) and
16.9 nm (21% polydispersity), respectively]. However, unlike Aβ-isolated IVIg, Avastin eluants
did not contain DLS detectable IgG monomers, although by SEC some IgG molecules eluted
near the elution volume for monomeric IgG (Fig 8A).
ELISA studies established that Aβ-isolated Avastin IgGs had ~120- stronger binding to
plate-immobilized PFs than the unfractionated antibody, with an EC50 of 11 ± 0.2 nM (Fig 8A
and Table 2). Notably, Aβ-isolated Avastin and IVIg IgGs had similar avidity for PFs, but the
mAb had a ~6-fold lower maximum binding signal (Fig 8B and Table 2). To further investigate
PFs binding by Avastin aggregates, we generated heat-induced aggregates. Fig 8B shows that
soluble and insoluble conformers of heat-treated Avastin had ~4-fold greater and ~about the
same avidity for PFs than the untreated mAb, respectively, with EC50s of ~300 nM and ~1 μM.
Moreover, the heat-treated mAb had a ~8-fold larger maximum PFs binding signal than was
obtained for the untreated IgG (Fig 8B).
Given that both Avastin and Synagis targeted aggregates of Aβ and TTR, we further investi-
gated if amyloidogenic aggregate binding was an inherent property of IgGs using human mye-
loma mAbs, which were representative of the four Ig isotypes (IgG1, IgG2, IgG3, and IgG4). All
unfractionated myeloma mAbs recognized PFs, with EC50s of ~500 nM, and the IgGs did not
target solution-phase Aβmonomers (S1 Fig). Moreover, like the other IgGs tested, SEC-iso-
lated dimers and HMW aggregates of one of the myeloma mAbs had up to ~40- and ~10-fold
stronger binding to PFs and SAgg, respectively, than the monomeric antibody (S1 Fig).
Discussion
IgG conformer binding to amyloidogenic aggregates
PAbs isolated from pooled normal human plasmas can specifically recognize conformational
epitopes on amyloidogenic conformers, and have demonstrated therapeutic potential for amy-
loid diseases [21, 22, 49]. However, the physiological and clinical significance of pAb's anti-
amyloidogenicity is unknown. Presumably, this is in part because pAb preparations contain a
complex mixture of IgG conformers (monomers, dimers, HMW aggregates) of naturally occur-
ring and antigen generated antibodies [14, 16, 50]. To address this, we have now established
the anti-amyloid activities of IgG conformer's contained in preparations of protein A-purified
and commercial (IVIg) pAbs.
Our studies have three main findings. The first observation is that SEC-isolated aggregates
of pAbs have greater avidity for aggregates of Aβ and TTR than pAb monomers (HMW
(with respect to Avastin) of a N-terminal 165-amino acid fragment of its immunogen VEGF (VEGF-165). Control IP experiments (Ctls) were carried out using
5 μg/mL mAb 6E10 and a mixture of Aβ dimers and PFs, or with 20 μg/mL Avastin and 1 μg/mL VEGF-165. The blots were probed for Aβ and VEGF-165
using mAb 6E10 and Avastin, respectively. In IPs carried out in the absence of VEGF-165, cross-reactivity of the secondary antibody, goat anti-human IgG
(heavy and light, Jackson Immunoresearch Laboratories Inc), with Avastin’s Ig light chain caused a faint band that migrated near VEGF-165. (C) Avastin IgG
conformers binding curves against plate-immobilized PFs in the presence or absence of a 1:10 dilution of IgG-depleted normal human sera. (D) Bar charts for
solution-phase PF's, Aβmonomers, and non-amyloid native and aggregated molecule's inhibition of Avastin monomers an dimers binding to plate-
immobilized PFs. Competition studies were carried out using 0.1 mg/mL competitors and concentrations of Avastin conformers that were equivalent to their
EC50 values for PFs: 500 nM IgGMon, and 200 nM IgG dimer. Each competition curve was carried out in duplicate, and bars represent the standard error.
doi:10.1371/journal.pone.0137344.g007
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species> dimers>monomers). Notably, IgG conformer's retention of binding to PFs in the
presence of normal human sera and non-amyloid molecules indicates that this activity may
have physiological relevance and clinical significance for amyloid diseases. A second main find-
ing is that great care must be taken when establishing pAb's binding to amyloidogenic aggre-
gates since trace IgG aggregates formed during sample processing can modulate their activity.
The last major finding is that IgGs have an inherent ability to recognize amyloidogenic aggre-
gates, and pAb's interactions with amyloidogenic aggregates at least partially involves uncon-
ventional (non-CDR) interactions of F(ab)ˈ regions. The latter finding indicates that pAb's
anti-amyloidogenicity is not restricted to natural antibodies [51, 52]. Instead, their activity
must encompass both naturally occurring IgGs and other antibodies that are generated by anti-
genic stimulation. Moreover, our demonstration that the F(ab) region of IVIg IgGs was critical
for amyloidogenic conformer binding, as well as a recent study implicating their requirement
Fig 8. Aβ-isolated but not heat-induced Avastin aggregates have enhanced avidity for PFs. (A) Left panel: SEC chromatograms for 0.3 mg/mL of Aβ-
isolated Avastin IgGs, untreated Avastin, and for the antibody diluted into elution buffer (0.1 M glycine, pH 2.7) that was used to elute Aβ-bound Avastin IgGs.
SEC was carried out using a Superdex 200 increase 10/300 GL column (GE Healthcare) that was equilibrated with PBS, pH 7.4. Right panel: Antibody
binding curves against PFs for unfractionated IVIg and Avastin, and for Aβ-isolated Avastin IgGs. (B) Left panel: SEC chromatograms for ~5 mg/mL of
unfractionated Avastin in PBS, pH 7.4, and for IgG conformers contained in supernatant of 71°C heated Avastin monomers (A400nm 0.5 sup) in PBS, pH 7.4.
Right panel: Antibody binding curves against PFs for soluble (A400nm 0.5 sup) and insoluble (A400nm 0.5 pellet) IgG conformers of heat-treated Avastin
monomers, and for untreated Avastin and IVIg.
doi:10.1371/journal.pone.0137344.g008
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for IVIg's immune modulation of T cell immune diseases [53], suggests that Fab- as well as Fc-
dependent mechanisms significantly contribute to IVIg's ability to modulate pathogenic
processes.
The stronger binding of aggregated than monomeric IgGs to amyloidogenic conformers
indicates that avidity effects (multidentate binding) were crucial. Moreover, similar PFs bind-
ing by F(ab) fragments generated from dye-isolated (aggregate-rich) IVIg IgGs and unfractio-
nated IVIg further indicated the central role that avidity effects had on IgG binding to
amyloidogenic conformers. Avidity effects alone can strengthen antibody binding to amyloido-
genic aggregates, and in doing so, induce preferential antibody binding to aggregated as
opposed to monomeric amyloidogenic conformers [54, 55]. However, pAb's preferential bind-
ing to amyloidogenic aggregates also likely relies on aggregate-associated conformational epi-
topes [20, 21, 27]. Moreover, heat aggregated IVIg's and Avastin's lack of enhanced avidity for
PFs, indicated that not all IgG aggregates have optimal spacing and/or exposure of amyloid-
reactive surface(s) for efficient multi-dentate binding. IgG aggregates with enhanced binding to
amyloidogenic conformers seem to be ubiquitously present in IgG products since they were
contained in preparations of both IVIg (Gammagard liquid1, Baxter International Inc) and
mAbs (Avastin, Synagis, and isotype control myeloma human IgGs). The modulation of IVIg's
binding to PFs due to the formation of trace HMW IgG aggregates [56, 57] on buffer exchange
of the antibody demonstrated that handling conditions normally sufficient for maintaining
IgG activity may not be adequate when establishing the anti-amyloid activity of pAbs. Presum-
ably, this is because pAb's moderate, high nM range, binding to amyloidogenic conformers can
be more easily enhanced by trace aggregates than conventional low nM binding of IgGs to anti-
gens. Thus, to ensure that SEC-isolated pAb and mAb conformer's anti-amyloidogenicities
were not modulated by contaminating IgG aggregates, we routinely used freshly prepared IgG
samples and confirmed their purities with DLS. Notably, it was not necessary to SEC remove
trace aggregates in unprocessed IVIg preparations since IgG conformers in these preparations
are very stable when stored and handled according to manufacturer's instructions, and they
contain only a small amount of IgG aggregates (by our estimates Gammagard liquid1, Baxter
International Inc, contained ~5% IgG dimers and<0.1% HMW IgG aggregates).
Given IgG aggregates had enhanced anti-amyloid activity compared with their monomeric
forms, it is possible that aggregates formed by other proteins [47, 48] may also have improved
binding to amyloidogenic conformers. If so, the latter mechanism does not seem to be a com-
mon property of aggregated proteins since, using capture ELSIA, we obtained significantly less
PFs binding for aggregated than native forms of two Aβ-reactive proteins: TTR (fibrils and
SAgg) [58] and lysozyme (fibrils) [59] (data not shown). Moreover, non-amyloid aggregates
formed by elastin fibrils and carboxymethylated ovalbumin did not recognize PFs.
The non-conventional (non-CDRs) component to pAb's binding to amyloidogenic con-
formers is poorly understood. Nevertheless, this activity seems to be diverse since high salt
(PBS containing 0.6 M NaCl versus PBS) strongly inhibited Synagis's but not Avastin's binding
to PFs (data not shown). Moreover, the much lower maximum binding signals for mAbs than
pAbs against PFs and SAgg indicates that only pAbs had sufficient antibody diversity to satu-
rate all non-conventional IgG binding sites. Alternatively, the larger pAbs binding signals may
have been due to contributions from both non-conventional and standard CDR-driven IgG
interactions. Presumably, the relatively low enhancement (~40-fold) of Abeta-isolated IVIg
IgGs binding to PFs compared with the amount of IgGs that were captured (~0.1 to 0.2% of
total IVIg passed through the column [27]) was because a relatively large amount of moder-
ately reactive non-conventional binding IgGs were isolated in addition to high reactive IgGs
(primarily aggregates). Our inability to deplete IVIg of moderately Abeta-reactive IgGs after
multiple passages of the antibody through an Abeta column indicates that this antibody
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population constituted a large portion of IVIg and its activity was consistent with IgG's inher-
ent ability to bind to amyloidogenic conformers.
Non-conventional IgG binding to amyloidogenic conformers is analogous to antibody recog-
nition of B-cell super-antigens, nucleotides, catalytic substrates, activated complement compo-
nents C4b and C3b, and CD4 [60–63]. Although the non-CDR antibody surface(s) that target
amyloidogenic conformers is not yet known, VH hinge regions of human IgGs can bind Aβ [64],
and VL framework regions (FRs) may target Aβ and non-native TTR in the first step of a split-
site mechanism for antibody proteolysis [65–68]. Our findings indicate that the latter mecha-
nism is the most plausible for the inherent anti-amyloid activity of IgGs since PFs were recog-
nized by VL FRs containing, hinge lacking, IVIg F(abˈ)s. Moreover, myeloma mAbs that are
representative of the different IgG isotypes have diverse hinge regions but similar binding to PFs.
The moderately stronger PFs binding by dimers and HMW aggregates of pAbs than mAbs
may be because pAb conformers were stabilized by end to end F(ab) arm interactions of anti-
idiotypic-idiotypic pairs [16] and Fc-Fc interactions [68]. In contrast, mAbs usually form
homo- and heterogeneous aggregates that are stabilized by contacts between F(ab)s and/or Fcs
[69]. Differential IgG activities may also have been due to differences in antibody sequence,
post-translational modification(s), antibody conformational isomerism and/or the IgG's pro-
pensities for multi-dentate binding [69–73].
Physiological significance and clinical utility
Our observations that human IgGs inherently bind to amyloidogenic conformers suggests it is
a homeostatic function for clearing and/or neutralizing extracellular amyloid-like misfolded
proteins [74, 75]. Evidence for this includes: 1) The retention of pAb and control mAb confor-
mer's anti-amyloidogenicities when dosed into normal human sera and in the presence of non-
amyloid molecules (Figs 1, 5 and 7) [27, 76], 2) IgG-Aβ complexes exist in normal human
blood and CSF [45, 77, 78], and 3) IgGs isolated from normal human plasma can clear amyloid
deposits in vivo and improve cognition in certain transgenic mice [21, 49]. Advancing current
poor understanding on the molecular basis for IgG's inherent anti-amyloid activity may not
only give novel insight in to their physiological functions, but the anti-amyloidogenicity of
other Ig-fold containing proteins. Such proteins includes those that are already known to bind
amyloidogenic conformers and mediate their cytotoxicity, such as, the receptor for advanced
glycation end products (RAGE) [79–83], LilrB2 [84], and FcγRIIb [85].
The clinical utility of the non-conventional anti-amyloid binding of IgGs for amyloid dis-
eases is unknown. Any candidate anti-amyloid therapeutic that is developed would have to be
more potent than the anti-amyloid activity of ~10 mg/mL of endogenous IgGs that is present
in a patient's blood. One such reagent may be monomeric IgG that is genetically engineered for
optimal unconventional binding to amyloidogenic conformers. It remains to be determined if
non-conventionally bound amyloidogenic conformers can be cleared by IgGs in the same man-
ner as classically (CDRs) bound forms. For example, in vivo, anti-Aβ IgGs can clear cerebral
Aβ through several not mutually exclusive mechanisms, including Fc-mediated clearance,
efflux of IgG-Aβ complexes to the periphery, and by a peripheral sink mechanism [86, 87].
Nevertheless, IgGs ability to recognize amyloidogenic conformers in several different ways
may be exploited as bifunctional therapeutic molecules, whereby amyloidogenic conformers
are bound to the IgG via non-classical interactions, while classical (CDR) binding of the anti-
body is used to stimulate additional therapeutic pathways, such as the expansion of regulatory
T cells [88]
Despite the enhanced binding of IgG aggregates (dimers and HMW species) to amyloido-
genic aggregates, these conformers are unsuitable as therapeutic reagents since IgG aggregates
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are prone to adverse in vivo inflammation and off-target binding [89], and consequently are
purposely removed during the production of IVIg [90]. Notably, both pAb dimer's and HMW
aggregate containing Aβ-isolated IVIg IgG's had greater 'stickiness' than the monomeric anti-
body against plate-immobilized non-amyloid molecules (Fig 5). Lastly, given a candidate non-
conventional anti-amyloid binding therapeutic IgG would recognize common epitopes on
amyloidogenic conformers, in vivo off-target binding of the monomeric antibody may occur
with amyloid deposits that are associated with normal aging [91].
Supporting Information
S1 Fig. Human IgGs have inherent reactivity with amyloidogenic conformers. (A) Antibody
binding curves against plate-immobilized PFs for IVIg and myeloma mAbs that were represen-
tative of the different Ig isotypes, IgG1, IgG2, IgG3, and IgG4. (B) Representative competition
curves for one of the mAb's, IgG2, and IVIg, show the antibody's preferential binding to aggre-
gated Aβ, with IC50s of ~3 μg/mL. Antibody binding curves against PFs (C) and SAgg (D) are
shown for unfractionated and SEC-isolated conformers of myeloma IgG2 mAb. Antibody
binding studies were carried out in duplicate and bars represent the standard error.
(EPS)
S2 Fig. Solution-phase PFs dose-dependent inhibition of Avastin dimers binding to plate-
immobilized PFs. The competition curves show that only PFs was a potent inhibitor of Avas-
tin dimers binding to immobilized PFs. Competition studies were carried out using a concen-
tration of Avastin dimers (200 nM) that was equivalent to its EC50 value for PFs.
(EPS)
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